Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NCEP Statin Recommendations Challenged By CSPI, Researchers

This article was originally published in The Tan Sheet

Executive Summary

The Center for Science in the Public Interest and a cohort of researchers are calling for an independent re-evaluation of the scientific data used by NIH's National Cholesterol Education Program to justify lowering the threshold for statin therapy

You may also be interested in...



Today’s Statin Debate Bears Lessons For Tomorrow’s Cholesterol Drugs

Clinicians recently took to the pages of the Journal of the American Medical Association to argue the appropriateness of using statin therapy as primary prevention in patients who are not already at high risk for a cardiovascular event. Such scrutiny comes as NIH prepares to issue new treatment guidelines to a market newly saturated with popular generic options, and as pharmaceutical companies assess how best to approach the dyslipidemia field.

2012 Wild Card: Will Guideline Revisions Drive Demand For Better Drugs?

Mevacor OTC Study Shows High-Risk Users Will “Upstream,” Merck Says

Merck's educational strategy for potential over-the counter sale of 20 mg Mevacor (lovastatin) will prevent rather than increase undertreatment among people who should be using more aggressive statin therapy, the firm contends

Topics

UsernamePublicRestriction

Register

PS097359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel